BlogTalkRadio uses cookies. By using our services, you're agreeing to our Cookies Policy. Got it

Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

Myeloma Crowd Radio: Thomas Martin, MD UCSF

  • Broadcast in Health
Myeloma Crowd Radio

Myeloma Crowd Radio

×  

Follow This Show

If you liked this show, you should follow Myeloma Crowd Radio.
h:539173
s:11751498
archived

Isatuxiab (Sarclisa) by Sanofi Genzyme is a new CD38-targeting monoclonal antibody that is now FDA approved to be combined with pomalidomide and dexamethasone. In the same drug class as daratumumab, isatuximab is different in its mechanism and is now being used in additional clinical trials in combinations such as isatuximab/carfilzomib/dex and isatuximab/bortezomib/dex. The growing number of potential therapies is a big win for myeloma patients. Learn from myeloma specialist Thomas Martin, MD of the University of California at San Francisco about how the drug works, how it is being applied in the myeloma clinic and open clinical trials using it in new combinations. Dr. Martin will also cover the recent clinical trial results presented at the recent ASCO 2020 meeting. 

 

Thanks to our episode sponsor, Takeda Oncology

 

Comments